MX365075B - Virus de arn oncolitico geneticamente estable, metodo de fabricacion y uso de los mismos. - Google Patents

Virus de arn oncolitico geneticamente estable, metodo de fabricacion y uso de los mismos.

Info

Publication number
MX365075B
MX365075B MX2016000462A MX2016000462A MX365075B MX 365075 B MX365075 B MX 365075B MX 2016000462 A MX2016000462 A MX 2016000462A MX 2016000462 A MX2016000462 A MX 2016000462A MX 365075 B MX365075 B MX 365075B
Authority
MX
Mexico
Prior art keywords
virus
manufacturing
human
rna virus
modified
Prior art date
Application number
MX2016000462A
Other languages
English (en)
Other versions
MX2016000462A (es
Inventor
Venskus Dite
Pjanova Dace
Petrovska Ramona
Auzins Jurgis
Kalvins Ivars
Original Assignee
Ditesan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ditesan Ltd filed Critical Ditesan Ltd
Publication of MX2016000462A publication Critical patent/MX2016000462A/es
Publication of MX365075B publication Critical patent/MX365075B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un método para fabricar un enterovirus modificado de tipo ECHO 7 por la modificación del virus nativo ECHO 7, aislado por un método conocido a partir heces humanas e identificado por la secuencia de genoma, la modificación se realiza inicialmente llevando a cabo la adaptación del virus en células cancerosas, atenuadas por un agente anticanceroso de dacarbazina, además pasando el virus modificado en cultivo de fibroblastos embrionarios humanos, seguido de la propagación en células de melanoma humano y después pasándolo en cultivo de fibroblastos embrionarios humanos que fueron tratados por ribavirin, aislados y purificados por un método conocido. El virus modificado es adecuado para el tratamiento de varios tumores.
MX2016000462A 2013-07-16 2014-07-16 Virus de arn oncolitico geneticamente estable, metodo de fabricacion y uso de los mismos. MX365075B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13176757.6A EP2826856B9 (en) 2013-07-16 2013-07-16 Genetically stable oncolytic RNA virus, method of manufacturing and use thereof
PCT/EP2014/065277 WO2015007788A1 (en) 2013-07-16 2014-07-16 Genetically stable oncolytic rna virus, method of manufacturing and use thereof

Publications (2)

Publication Number Publication Date
MX2016000462A MX2016000462A (es) 2016-07-26
MX365075B true MX365075B (es) 2019-05-22

Family

ID=48790285

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016000462A MX365075B (es) 2013-07-16 2014-07-16 Virus de arn oncolitico geneticamente estable, metodo de fabricacion y uso de los mismos.

Country Status (16)

Country Link
US (2) US10174291B2 (es)
EP (2) EP2826856B9 (es)
JP (1) JP6293882B2 (es)
CN (2) CN105518128B (es)
AU (1) AU2014292114B2 (es)
BR (1) BR112016000874B1 (es)
CA (1) CA2917584C (es)
EA (1) EA032977B1 (es)
ES (1) ES2566146T3 (es)
GE (1) GEP201706763B (es)
HK (1) HK1219500A1 (es)
MD (1) MD4480C1 (es)
MX (1) MX365075B (es)
PL (2) PL2826856T3 (es)
UA (1) UA116387C2 (es)
WO (1) WO2015007788A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109276580B (zh) * 2017-07-21 2021-08-24 厦门大学 一种用于治疗肿瘤的病毒
CN109419818B (zh) * 2017-08-24 2021-08-10 厦门大学 一种用于治疗肿瘤的埃可病毒
CN107669707A (zh) * 2017-11-16 2018-02-09 邹罡 埃可病毒作为溶瘤病毒在抗肿瘤中的应用
CN110064044B (zh) * 2018-01-20 2022-09-09 中国科学院武汉病毒研究所 一种肠道病毒71型的抑制剂及应用
GB201808500D0 (en) 2018-05-23 2018-07-11 Ditesan Ltd Virus and virus use
WO2020035423A1 (en) 2018-08-13 2020-02-20 Ditesan Ltd. Combination therapy of cancer by administrating echo-7 virus and a pharmaceutically effective anti-cancer drug

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4987101A (en) 1988-12-16 1991-01-22 International Business Machines Corporation Method for providing improved insulation in VLSI and ULSI circuits
CN1244583A (zh) * 1998-08-12 2000-02-16 财团法人生物技术开发中心 本土性猪水泡病病毒与其变异株的制备方法及用途
CA2386920C (en) * 1999-09-17 2012-01-24 Pro-Virus, Inc. Oncolytic virus
AUPQ425699A0 (en) * 1999-11-25 1999-12-23 University Of Newcastle Research Associates Limited, The A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US6602862B1 (en) * 2000-09-19 2003-08-05 Merz Pharma Gmbh & Co., Kgaa 1-Amino-alkylcyclohexanes as trypanocidal agents
WO2002072027A2 (en) * 2001-03-14 2002-09-19 University Of Alabama Research Foundation Oncolytic rna replicons
LV12861B (lv) 2002-06-14 2002-10-20 Aina Muceniece Imūnstimulators ar pretaudzēja aktivitāti un tā iegūšanas paņēmiens
AU2002953436A0 (en) * 2002-12-18 2003-01-09 The University Of Newcastle Research Associates Limited A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
WO2004094454A2 (en) * 2003-04-18 2004-11-04 Idm Pharma, Inc. Hla-a2 tumor associated antigen peptides and compositions
WO2006074526A1 (en) * 2005-01-17 2006-07-20 Viralytics Limited Method and composition for treatment of neoplasms
CA2673520A1 (en) * 2006-12-22 2008-07-03 Bayer Schering Pharma Aktiengesellschaft Generation of oncolytic adenoviruses and uses thereof
US10722562B2 (en) * 2008-07-23 2020-07-28 Immudex Aps Combinatorial analysis and repair
CA2689707A1 (en) * 2009-11-16 2011-05-16 Jean-Simon Diallo Identification of the novel small molecule viral sensitizer vse1 using high-throughput screening

Also Published As

Publication number Publication date
UA116387C2 (uk) 2018-03-12
US10174291B2 (en) 2019-01-08
EP2826856B9 (en) 2016-05-04
HK1219500A1 (zh) 2017-04-07
EA201690232A1 (ru) 2016-05-31
US20190144833A1 (en) 2019-05-16
EP3022297A1 (en) 2016-05-25
MX2016000462A (es) 2016-07-26
JP2016529886A (ja) 2016-09-29
US20160376562A1 (en) 2016-12-29
EA032977B1 (ru) 2019-08-30
CA2917584A1 (en) 2015-01-22
ES2566146T3 (es) 2016-04-11
GEP201706763B (en) 2017-10-25
CN105518128A (zh) 2016-04-20
CN105518128B (zh) 2019-07-09
AU2014292114B2 (en) 2018-12-20
CN110129284A (zh) 2019-08-16
PL3022297T3 (pl) 2023-12-18
BR112016000874B1 (pt) 2019-07-16
JP6293882B2 (ja) 2018-03-14
WO2015007788A1 (en) 2015-01-22
CA2917584C (en) 2018-02-27
PL2826856T3 (pl) 2016-06-30
EP3022297B1 (en) 2023-07-05
EP2826856B1 (en) 2015-12-23
EP3022297C0 (en) 2023-07-05
BR112016000874A2 (pt) 2017-03-21
AU2014292114A1 (en) 2016-02-18
MD4480C1 (ro) 2017-12-31
MD20160014A2 (ro) 2016-07-31
EP2826856A1 (en) 2015-01-21
US10435672B2 (en) 2019-10-08
MD4480B1 (ro) 2017-05-31

Similar Documents

Publication Publication Date Title
GEP201706763B (en) Genetically stable oncolytic rna virus, method of manufacturing and use thereof
TN2015000353A1 (en) Newcastle disease viruses and uses thereof
SA518400424B1 (ar) جزيئات الجسم المضاد لعلاج السرطان
EA201791443A1 (ru) Естественные киллерные клетки и их применения
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
MX2018004600A (es) Celulas aniquiladoras naturales y células ilc3 y usos de las mismas.
IN2012DN01920A (es)
NZ601325A (en) Compositions and methods for treating glioblastoma gbm
EP3372685A3 (en) Cell lines for virus production and methods of use
MX2015007751A (es) Anticuerpos anti-gdf15.
MX2011010908A (es) Anticuerpos anti-tnf-alfa y sus usos.
MX2015005963A (es) Inhibidores heterociclicos de glutaminasa.
MX353476B (es) Anticuerpos anti-cxcl13 y metodos para usarlos.
EA201590747A1 (ru) Способы лечения с использованием аденовируса
NZ595641A (en) Humanized anti-egfl7 antibodies and methods using same
MX2016005824A (es) Metodo de cultivo celular.
EA201001266A1 (ru) Эффективные противоопухолевые парамиксовирусы
EA201891335A1 (ru) Добавление аргинина с целью повышения эффективности ацетогенов, ферментирующих газ
MX2015012063A (es) Oligonucleotidos antisentido para el tratamiento de celulas madre del cancer.
MX2013007055A (es) Derivados de sanglifehrina y metodos para su produccion.
MX2020005251A (es) Composiciones para mejorar la funcionalidad de células car-t y uso de las mismas.
MX2016012104A (es) Compuestos de azabenzofurano que contienen ciano para el tratamiento de la hepatitis c.
MX2023012266A (es) Un fab anti-tslp con estabilidad mejorada.
EA202092991A1 (ru) Модифицированные направляющие рнк, которые используются для редактирования генома
MY185444A (en) Enterovirus 71 antiviral peptides

Legal Events

Date Code Title Description
FG Grant or registration